Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer

Rama, Ana R.; Jiménez-López, Julia; Cabeza, Laura; Jiménez-Luna, Cristina; Leiva, María C.; Perazzoli, Gloria; Hernández, Rosa María; Zafra, Inmaculada; Ortíz, Raúl; Melguizo, Consolación; Prados, José Luis Paniza

doi:10.2174/1567201813666151203232852

Cited by 20 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We envisage validating its ability to predict patientspecific clinical responses in the context of follow-up studies. Furthermore, our culture system may also prove suitable for studying basic aspects of cancer immune-biology or testing therapies whose efficacy is influenced by whole TME (e.g., drug-loaded nanoparticles, [41] targeting mesenchymal or immune cells, including TGF-β blockers, [42] bispecific antibodies, [43] or checkpoint inhibitors, [44] currently under clinical investigation for CRC).…”

Section: Discussionmentioning

confidence: 99%

Maintenance of Primary Human Colorectal Cancer Microenvironment Using a Perfusion Bioreactor‐Based 3D Culture System

et al. 2019

View full text Add to dashboard Cite

Immunotherapy has emerged during the past two decades as an innovative and successful form of cancer treatment. However, frequently, mechanisms of actions are still unclear, predictive markers are insufficiently characterized, and preclinical assays for innovative treatments are poorly reliable. In this context, the analysis of tumor/immune system interaction plays key roles, but may be unreliably mirrored by in vivo experimental models and standard bidimensional culture systems. Tridimensional cultures of tumor cells have been developed to bridge the gap between in vitro and in vivo systems. Interestingly, defined aspects of the interaction of cells from adaptive and innate immune systems and tumor cells may also be mirrored by 3D cultures. Here we review in vitro models of cancer/immune cell interaction and we propose that updated technologies might help develop innovative treatments, identify biologicals of potential clinical relevance, and select patients eligible for immunotherapy treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Maintenance of Primary Human Colorectal Cancer Microenvironment Using a Perfusion Bioreactor‐Based 3D Culture System

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, they can be coupled with antibodies that recognize tumor cells or receptors (like folic acid) to boost drug release in an acidic environment. They can also be manufactured in pH‐sensitive formulations 103 …”

Section: Approaches Of Nps In Oral Cancer Treatments and Detectionmentioning

confidence: 99%

Nanoplatforms: The future of oral cancer treatment

Senevirathna

Jayawickrama

Jayasinghe

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsCytotoxicity is a key disadvantage of using chemotherapeutic drugs to treat cancer. This can be overcome by encapsulating chemotherapeutic drugs in suitable carriers for targeted delivery, allowing them to be released only at the cancerous sites. Herein, we aim to review the recent scientific developments in the utilization of nanotechnology‐based drug delivery systems for treating oral malignancies that can lead to further improvements in clinical practice.MethodsA comprehensive literature search was conducted on PubMed, Google Scholar, ScienceDirect, and other notable databases to identify recent peer‐reviewed clinical trials, reviews, and research articles related to nanoplatforms and their applications in oral cancer treatment.ResultsNanoplatforms offer a revolutionary strategy to overcome the challenges associated with conventional oral cancer treatments, such as poor drug solubility, non‐specific targeting, and systemic toxicity. These nanoscale drug delivery systems encompass various formulations, including liposomes, polymeric nanoparticles, dendrimers, and hydrogels, which facilitate controlled release and targeted delivery of therapeutic agents to oral cancer sites. By exploiting the enhanced permeability and retention effect, Nanoplatforms accumulate preferentially in the tumor microenvironment, increasing drug concentration and minimizing damage to healthy tissues. Additionally, nanoplatforms can be engineered to carry multiple drugs or a combination of drugs and diagnostic agents, enabling personalized and precise treatment approaches.ConclusionThe utilization of nanoplatforms in oral cancer treatment holds significant promise in revolutionizing therapeutic strategies. Despite the promising results in preclinical studies, further research is required to evaluate the safety, efficacy, and long‐term effects of nanoformulations in clinical settings. If successfully translated into clinical practice, nanoplatform‐based therapies have the potential to improve patient outcomes, reduce side effects, and pave the way for more personalized and effective oral cancer treatments.

show abstract

“…Among these platforms, lipid-based nanoparticles have some of the lowest toxicity in in vivo experiments, having the ability to carry hydrophilic or hydrophobic molecules and extend the duration of action, which means prolonged half-life and a controlled drug release. Lipid-based NPs can be subjected to chemical adjustment to bypass the immune system's detection, such as PEG, or can be attached to antibodies to recognize the tumour cells receptors, like folic acid (FoA) [65]. Lipid NPs can be prepared as sensitive PH formulations to enhance the drug release in acidic conditions [66].…”

Section: Nano Systems In Inflammationmentioning

confidence: 99%

Microfluidics Technology for the Design and Formulation of Nanomedicines

et al. 2021

View full text Add to dashboard Cite

In conventional drug administration, drug molecules cross multiple biological barriers, distribute randomly in the tissues, and can release insufficient concentrations at the desired pathological site. Controlling the delivery of the molecules can increase the concentration of the drug in the desired location, leading to improved efficacy, and reducing the unwanted effects of the molecules under investigation. Nanoparticles (NPs), have shown a distinctive potential in targeting drugs due to their unique properties, such as large surface area and quantum properties. A variety of NPs have been used over the years for the encapsulation of different drugs and biologics, acting as drug carriers, including lipid-based and polymeric NPs. Applying NP platforms in medicines significantly improves the disease diagnosis and therapy. Several conventional methods have been used for the manufacturing of drug loaded NPs, with conventional manufacturing methods having several limitations, leading to multiple drawbacks, including NPs with large particle size and broad size distribution (high polydispersity index), besides the unreproducible formulation and high batch-to-batch variability. Therefore, new methods such as microfluidics (MFs) need to be investigated more thoroughly. MFs, is a novel manufacturing method that uses microchannels to produce a size-controlled and monodispersed NP formulation. In this review, different formulation methods of polymeric and lipid-based NPs will be discussed, emphasizing the different manufacturing methods and their advantages and limitations and how microfluidics has the capacity to overcome these limitations and improve the role of NPs as an effective drug delivery system.

show abstract

Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer

Cited by 20 publications

References 0 publications

Maintenance of Primary Human Colorectal Cancer Microenvironment Using a Perfusion Bioreactor‐Based 3D Culture System

Maintenance of Primary Human Colorectal Cancer Microenvironment Using a Perfusion Bioreactor‐Based 3D Culture System

Nanoplatforms: The future of oral cancer treatment

Microfluidics Technology for the Design and Formulation of Nanomedicines

Contact Info

Product

Resources

About